Behavioral disturbances of dementia

Journal of Geriatric Psychiatry and Neurology

Volumn 11, Issue 4, 1998, Pages 206-212

  Pollock, Bruce G ^a,b   Mulsant, Benoit H ^a  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; BUSPIRONE; CARBAMAZEPINE; CHLORPROMAZINE; CITALOPRAM; CLOZAPINE; DOPAMINE 2 RECEPTOR BLOCKING AGENT; FLUOXETINE; FLUVOXAMINE; HALOPERIDOL; LEVOMEPROMAZINE; NEUROLEPTIC AGENT; OLANZAPINE; PAROXETINE; PERPHENAZINE; RISPERIDONE; SEROTONIN UPTAKE INHIBITOR; THIORIDAZINE; TRAZODONE; VALPROIC ACID;

ANOREXIA; ANTICHOLINERGIC EFFECT; ASTHENIA; BEHAVIOR DISORDER; BLOOD DYSCRASIA; BRADYCARDIA; DAILY LIFE ACTIVITY; DELIRIUM; DEMENTIA; EXTRAPYRAMIDAL SYMPTOM; HEADACHE; HEART PALPITATION; HUMAN; NAUSEA; PRIORITY JOURNAL; REVIEW; SAFETY; SIDE EFFECT; SOMNOLENCE; VERTIGO;

EID: 0032439331     PISSN: 08919887     EISSN: None     Source Type: Journal    
DOI: 10.1177/089198879901100407     Document Type: Review

References (59)

1. Deutsch LH, Bylsma FW, Rovner BW, et al. Psychosis and physical aggression in probable Alzheimer's disease. Am J Psychiatry 1991; 148:1159-1163.
2. Health Care FinancingAdminstration: Transmittal 250. Washington, DC: Department of Health and Human Services, 1992.
3. Stewart JT. Managing the care of patients with dementia: how to maximize level of functioning and minimize behavior problems. Postgrad Med 1991; 90:45-49.
4. Levin HS, High WM, Goethe KE, et al. The Neurobehavioral Rating Scale: assessment of the behavioral sequelae of head injury by the clinician. J Neural Neurosurg Psychiatry 1987; 50:183-193.
5. Rosen J, Burgio L, Kollar M, et al. The Pittsburgh Agitation Scale: a user-friendly instrument for rating agitation in dementia patients. Am J Geriatr Psychiatry 1994; 2:52-59.
6. Pollock BG, Mulsant BH, Sweet RA, et al. Prospective cytochrome P450 phenotyping for neuroleptic treatment in dementia. Psychopharmacol Bull 1995; 31:327-332.
7. Ayd FJ. A survey of drug-induced extrapyramidal reactions. JAMA 1961; 175:1054-1060.
8. Jeste DV, Caligiuri MP, Paulsen JS, et al. Risk of tardive dyskinesia in older patients: a prospective study of 266 outpatients. Arch Gen Psychiatry 1995; 52:756-765.
9. Evans DAP, Maghoub A, Sloan TP, et al. A family and population study of the genetic polymorphism of debrisoquin oxidation in a white British population. J Med Genet 1980; 17: 102-105.
10. Brösen K. Are pharmacokinetic drug interactions with the SSRIs an issue? Int Clin Psychopharmacol 1996; IKsuppl l):23-27.
11. Armstrong M, Daly AK, Cholerton S, Bateman DN, Idle JR. Mutant debrisoquine hydroxylation genes in Parkinson's disease. Lancet 1992; 339:1017-1018.
12. Lingjaerde O, Ahlfors UG, Bech P, et al. The UKU side effect rating scale. Ada Psychiatr Scand Suppl 1987; 334:1-100.
13. Simpson GM, Angus JWS. A rating scale for extrapyramidal side effects. Ada Psychiatr Scand 1970; 212(suppl):ll-19.
14. Roberts GW, Leigh PN, Weinberger DR. Neuropsychiatrie disorders. St. Louis: Wolfe, 1993.
15. McKeith I, Fairbairn A, Perry R, et al. Neuroleptic sensitivity in patients with senile dementia of Lewy body type. BMJ 1992; 305:673-678.
16. Saitoh T, Xia Y, Chen X, et al. The CYP2D6B mutant allele is overrepresented in the Lewy body variant of Alzheimer's disease. Ann Neural 1995; 37:110-112.
17. Claghorn J, Honigfeld G, Abuzzahab PS, et al. The risks and benefits of clozapine versus chlorpromazine. J Clin Psychopharmacol 1987; 7:377-384.
18. Pitner JK, Mintzer JE, Pennypacker LC, et al. Efficacy and adverse effects of clozapine in four elderly psychotic patients. J Clin Psychiatry 1995; 56:180-185.
19. Jeste DV, Krull AJ. Behavioral problems associated with dementia: diagnosis and treatment. Geriatrics 1991; 46:28-34.
20. Miller CH, Mohr F, Umbricht D, Woerner M, et al. The prevalence of acute extrapyramidal signs and symptoms in patients treated with clozapine, risperidone and conventional antipsychotics. J Clin Psychiatry 1998; 59(2):69-75.
21. Kapur S, Remington G, Zipursky RB, et al. The D2 dopamine receptor occupancy of risperidone and its relationship to extrapyramidal symptoms: a PET study. Life Sei 1995; 57(10):PL103-PL107.
22. Katz I, Brecher M, Clyde C, et al. Risperidone in the treatment of psychosis and aggressive behavior in patients with dementia. Presented at the 11th Annual Meeting of the American Association for Geriatric Psychiatry, San Diego, CA, March 8-11,1998.
23. Tariot P, Gaile SE, Castelli NA, Ponsteinsson AP. Treatment of agitation in dementia. N Dir Mental Health Serv 1997; 76:109-123.
24. Allard PO, Rinne J, Marcusson JO. Dopamine uptake sites in Parkinson's disease and in dementia of the Alzheimer type. Brain Res 1994; 637:262-266.
25. Morgan DG, May PC, Finch CE. Dopamine and serotonin systems in human and rodent brain: effects of age and neurodegenerative disease. J Am GeriatrSoc 1987; 35:334-335.
26. Pollock BG, Mulsant BH, Sweet R, et al. An open pilot study of citalopram for behavioral disturbances of dementia. Am J Geriatr Psychiatry 1997; 5:70-78.
27. Tariot PN, Rosemary E, Podgorski CA, et al. Efficacy and tolerability of carbamazepine for agitation and aggression in dementia. Am J Psychiatry 1998; 155:54-61.
28. Tariot PN, Schneider LS, Katz IR. Anticonvulsant and other non-neuroleptic treatments of agitation in dementia. J Geriatr Psychiatry Neural 1995; 8(suppl 1):S28-S39.
29. Chambers CA, Bain J, Rosbottom R, et al. Carbamazepine in senile dementia and overactivity-placebo controlled doubleblind trial. IRCS Med Sei 1982; 10:505-506.
30. Tariot PN, Erb R, Leibovici A, et al. Carbamazepine treatment of agitation in nursing home patients with dementia: a preliminary study. JAm GeriatrSoc 1994; 42:1160-1166.
31. Cooney C, Mortimer A, Smith A, et al. Carbamazepine use in aggressive behavior associated with senile dementia. Int J Geriatr Psychiatry 1996; 11:901-905.
32. Herrmann N, Lanctôt KL. From transmitters to treatment: the pharmacotherapy of behavioral disturbances in dementia. Can J Psychiatry 1997; 42(suppl 1):51S-64S.
33. Gates M, Powers R. Concomitant rash and blood dyscrasias in geriatric psychiatry patients treated with carbamazepine. Ann Pharmacother 1998; 32:884-887.
34. Lantz MS, Marin D. Pharmacologie treatment of agitation in dementia: a comprehensive review. J Geriatr Psychiatry Neurol 1996; 9:107-119.
35. Mellow AM, Solano-Lopez C, Davis S. Sodium valproate in the treatment of behavioral disturbance in dementia. J Geriatr Psychiatry Neural 1993; 6:205-209.
36. Mazure CM, Druss BG, Cellar JS. Valproate treatment of older psychotic patients with organic mental syndrome and behavioral dyscontrol. JAm Geriatr Sac 1992; 40:914-916.
37. Kunik ME, Puryear L, Orengo CA, et al. The efficacy and tolerability of divalproex sodium in elderly demented patients with behavioral disturbances. Int J Geriatr Psychiatry 1998; 13:29-34.
38. Narayan M, Nelson JC. Treatment of dementia with behavioral disturbance using divalproex or a combination of divalproex and a neuroleptic. J Clin Psychiatry 1997; 58:351-354.
39. Sival RC, Haffmans PMH, VanGert PP, et al. The effects of sodium valproate on disturbed behaviour in dementia. J GeriatrSoc 1994; 42:906-907.
40. Herrmann N. Valproic acid treatment of agitation in dementia. Can J Psychiatry 1998; 43:69-72.
41. Haas S, Vincent K, Holt J, Lippmann S. Divalproex; a possible treatment alternative for demented, elderly aggressive patients. Ann Clin Psychiatry 1997; 9:145-147.
42. Porsteinsson AP, Tariot PN, Erb R, et al. An open trial of valproate for agitation in geriatric neuropsychiatric disorders. Am J Geriatr Psychiatry 1997; 5:344-351.
43. Chen CP, Alder JT, Bowen DM, et al. Presynaptic serotonergic markers in community-aquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication. J Neurochem 1996; 66:1592-1598.
44. Cantillon M, Brunswick R, Molina D, et al. Buspirone vs haloperidol: a double-blind trial for agitation in a nursing home population with Alzheimer's disease. AmJ Geriatr Psychiatry 1996; 4:263-271.
45. Steinbeg JR. Anxiety in elderly patients. A comparison ofazapirones and benzodiazepines. Drugs Aging 1994; 5:335-345.
46. Strand M, Hetta J, Rosen A, et al. A double-blind controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 1990; 51(suppl):40-45.
47. Sultzer DL, Gray KF, Gunay I, et al. A double-blind comparison of trazodone and haloperidol for treatment of agitation in patients with dementia. Am J Geriatr Psychiatry 1997; 5:60-69.
48. Pollock BG. Drug interactions. In: Nelson JC, ed. Geriatric psychopharmacology. New York: Marcel Dekker, 1998:43-60.
49. Preskorn SH. Clinically relevant pharmacology of selective serotonin reuptake inhibitors: an overview with emphasis on pharmacokinetics and effects on oxidative drug metabolism. Clin Pharmacokinet 1997; 32(suppl 1):1-21.
50. Liu BA, Mittmann N, Knowles SR, et al. Hyponatremia and the syndrome of inappropriate secretion of antidiuretic hormone associated with the use of selective reuptake inhibitors: a review of spontaneous reports. Can Med Assoc J 1996; 155:519-527.
51. Olafsson K, Jorgensen S, Jensen HV, et al. Fluvoxamine in the treatment of demented elderly patients: a double-blind, placebocontrolled study. Acta Psychiatr Scand 1992; 85:453-456.
52. Mulsant BH, Pollock BG, Rosen J. New antidepressants and antipsychotics in the nursing home. Nurs Home Med 1997; 5:240-248.
53. Hyttel J. Pharmacological characterization of selective serotonin reuptake inhibitors (SSRIs). Int Clin Psychopharmacol 1994; 9(suppl l):19-26.
54. Nyth AL, Gottfries CG. The clinical efficacy of citalopram in treatment of emotional disturbances in dementia disorders: a Nordic multicentre study. Br J Psychiatry 1990; 157:894-901.
55. Gottfries CG. Neurochemistry and neurotransmitters. Int Psychogeriatr 1996; 8(suppl 3):225-231.
56. Vertainen H, et al. Citalopram, a selective serotonin reuptake inhibitor, in the treatment of aggression in schizophrenia. Acta Psychiatr Scand 1995; 91:348-351.
57. Syvalahti EK, Kallioniemi H, Lehto H. Citalopram in patients with unsatisfactory response to neuroleptics: an open followup study. Methods Find Exp Clin Pharmacol 1994; 16:49-55.
58. Salokangas RK, Saarijarvi S, Taiminen T, et al. Citalopram as an adjuvant in chronic schizophrenia: a double-blind placebo-controlled study. Acta Psychiatr Scand 1996; 94:175-180.
59. Gottfries CG. Scandinavian experience with citalopram in the elderly. Int Clin Psychopharmacol 1996; 11(suppl 1):41-44.